CEBPA and acute myeloid leukemia: Recurring molecular lesions identify AML patient subgroups with different survival probabilities; in fact, results from nucleophosmin 1 (NPM1), Fms-like tyrosine kinase 3 (FLT3), CCAAT/enhancer binding protein α (CEBPA) and tumor protein p53 (TP53) mutational screening genes have led to recommendations from the European LeukemiaNet Group that these be tested in routine practice [3].